FDA Requests Expanded Alcohol Warnings For Extended-Release Morphine Kadian
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.